109 related articles for article (PubMed ID: 24449987)
1. Indemonstrable axial spondyloarthritis: does it exist?
Slobodin G; Rosner I
Isr Med Assoc J; 2013 Dec; 15(12):780-1. PubMed ID: 24449987
[No Abstract] [Full Text] [Related]
2. Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab.
Otsuka A; Morita M; Yamada H
J Orthop Sci; 2015 Nov; 20(6):1070-7. PubMed ID: 26245191
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
Haibel H; Rudwaleit M; Brandt HC; Grozdanovic Z; Listing J; Kupper H; Braun J; Sieper J
Arthritis Rheum; 2006 Feb; 54(2):678-81. PubMed ID: 16447247
[No Abstract] [Full Text] [Related]
5. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
Poddubnyy D; Rudwaleit M
Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
[TBL] [Abstract][Full Text] [Related]
7. Spondyloarthropathies: ankylosing spondylitis and psoriatic arthritis.
Bennett DL; Ohashi K; El-Khoury GY
Radiol Clin North Am; 2004 Jan; 42(1):121-34. PubMed ID: 15049527
[TBL] [Abstract][Full Text] [Related]
8. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?
Kiltz U; Baraliakos X; Karakostas P; Igelmann M; Kalthoff L; Klink C; Krause D; Schmitz-Bortz E; Flörecke M; Bollow M; Braun J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1415-22. PubMed ID: 22505331
[TBL] [Abstract][Full Text] [Related]
9. Ankylosing Spondylitis and Axial Spondyloarthritis.
Taurog JD; Chhabra A; Colbert RA
N Engl J Med; 2016 Jun; 374(26):2563-74. PubMed ID: 27355535
[No Abstract] [Full Text] [Related]
10. The challenge of early diagnosis in ankylosing spondylitis.
O'Shea F; Salonen D; Inman R
J Rheumatol; 2007 Jan; 34(1):5-7. PubMed ID: 17216671
[No Abstract] [Full Text] [Related]
11. [Criteria of the treatment results of ankylosing spondylitis].
Nold F; Ott VR; Hentschel HD
Verh Dtsch Ges Rheumatol; 1969; 1():292-305. PubMed ID: 4997346
[No Abstract] [Full Text] [Related]
12. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
Cohen JD; Ferreira R; Jorgensen C
J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
[No Abstract] [Full Text] [Related]
13. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
14. Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics.
Appel H; Sieper J
Curr Rheumatol Rep; 2008 Oct; 10(5):356-63. PubMed ID: 18817638
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial.
Santra G; Sarkar RN; Phaujdar S; Banerjee S; Siddhanta S
Singapore Med J; 2010 Nov; 51(11):883-7. PubMed ID: 21140116
[TBL] [Abstract][Full Text] [Related]
17. Absence of radiographic progression at two years in a cohort of patients with non-radiographic axial spondyloarthritis treated with TNF-α blockers.
Almirall M; López-Velandia JG; Maymó J
Reumatol Clin; 2014; 10(2):134-5. PubMed ID: 23827199
[No Abstract] [Full Text] [Related]
18. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis.
Shima Y; Tomita T; Ishii T; Morishima A; Maeda Y; Ogata A; Kishimoto T; Tanaka T
Mod Rheumatol; 2011 Aug; 21(4):436-9. PubMed ID: 21308388
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of ankylosing spondylitis (Bechterew disease)].
Rudwaleit M; Sieper J
Dtsch Med Wochenschr; 2005 Aug; 130(33):1882-6. PubMed ID: 16118732
[No Abstract] [Full Text] [Related]
20. Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of Canada Spine and Sacroiliac Joint Magnetic Resonance Imaging Indices for Ankylosing Spondylitis.
Maksymowych WP; Lambert RG; Brown LS; Pangan AL
J Rheumatol; 2012 Aug; 39(8):1666-74. PubMed ID: 22753648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
